Annovis Bio, Inc. (ANVS) [Rocket]

In millions, except per share items	Jun-30-23	Mar-31-23	Dec-31-22	Sep-30-22	Jun-30-22	Mar-31-22	Dec-31-21	Sep-30-21
	10-Q	10-Q	10-K	10-Q	10-Q	10-Q	10-K	10-Q
Revenues	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Cost of goods sold	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Gross profit	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Selling, general and administrative [+]	7.6	8.1	9.0	10.4	9.6	8.3	6.1	3.5
General and administrative	7.6	8.1	9.0	10.4	9.6	8.3	6.1	3.5
Research and development	22.9	18.7	13.1	14.4	10.4	8.2	8.5	7.0
EBIT [+]	-30.6	-26.8	-22.1	-24.8	-20.0	-16.6	-14.5	-10.5
EBIT growth	52.9%	61.7%	51.8%	135.8%	115.6%	78.3%	118.9%	87.9%
Interest income	0.6	0.4	0.2	0.1	0.1	0.0	0.0	0.0
Interest income	0.6	0.4	0.2	0.1	0.1	0.0	0.0	0.0
Pre-tax income	-30.0	-26.4	-21.9	-24.7	-19.9	-16.5	-14.5	-10.3
Income taxes	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Tax rate	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Net income	-30.0	-26.4	-21.9	-24.7	-19.9	-16.5	-14.5	-10.3

Basic EPS [+]	($3.58)	($3.23)	($2.68)	($3.08)	($2.49)	($2.11)	($1.93)	($1.43)
Growth	44.0%	52.7%	38.9%	114.8%	102.5%	73.4%	117.8%	68.4%
Diluted EPS [+]	($3.58)	($3.23)	($2.68)	($3.08)	($2.49)	($2.11)	($1.93)	($1.43)
Growth	44.0%	52.7%	38.9%	114.8%	102.5%	73.4%	117.8%	68.4%

Shares outstanding (basic) [+]	8.4	8.2	8.2	8.0	8.0	7.8	7.5	7.2
Growth	4.4%	4.6%	8.8%	11.9%	16.7%	15.9%	21.8%	54.2%
Shares outstanding (diluted) [+]	8.4	8.2	8.2	8.0	8.0	7.8	7.5	7.2
Growth	4.4%	4.6%	8.8%	11.9%	16.7%	15.9%	21.8%	54.2%

EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges.